Tuesday, May 20 • 10:00 – 11:00 a.m. ET

The CLE focuses on the need for coordination between regulatory and IP submissions to maximize the chances of receiving both FDA approval and patent protection for biologic products. Panelists will discuss the timing and content of the various submissions to FDA throughout the product life cycle, focusing on the content relevant to patent claims, so that IP and regulatory attorneys can ensure consistency.

For more information, contact kimberly.macalister@troutman.com.

Insight Industries + Practices